Please login to the form below

Not currently logged in
Email:
Password:

Trial success for Novartis' psoriasis drug

Novartis has presented data at the European Academy of Dermatology and Venereology Congress that demonstrates investigational psoriasis treatment AIN457 is effective in up to 81 per cent of patients

Novartis has presented data at the European Academy of Dermatology and Venereology (EADV) Congress in Lisbon, Portugal, that demonstrates investigational psoriasis treatment AIN457 is effective in up to 81 per cent of patients.

The company said one phase II study showed 81 per cent of patients receiving AIN457 150mg subcutaneously once a month experienced at least a 75 per cent improvement of psoriasis signs and symptoms.

A separate study demonstrated 83 per cent of patients who were given an intravenous starting dose of AIN457 experienced at least a 75 per cent improvement of symptoms. This compared to 10 per cent of patients on placebo.

The treatment, a fully human monoclonal antibody neutralizing interleukin-17A that may provide a new mechanism of action for the treatment of immune-mediated diseases, was also shown to be more effective when used early on in the therapeutic process.

Dr Kim Papp, dermatologist and director of research at Probity Medical Research, Waterloo, Ontario, Canada, said the results suggest that AIN457 could bring "considerable improvement" to the lives of patients with psoriasis, and emphasised the fast-acting action of the drug.

John Hohneker, global head of development for Integrated Hospital Care at Novartis, said: "We are encouraged by these positive phase II results and look forward to receiving the results of larger-scale and longer-term phase III studies with AIN457 which began this year."

24th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics